Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WB-LDRT Combined With ICI and Intrathecal Chemotherapy for Refractory Meningeal Metastasis of Lung Cancer
NCT06431685Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab and pemetrexed in leptomeningeal metastasis (LM) and non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoints: Clinical response rate at 48 months and Incidence of treatment-related adverse events at 48 months. Started Apr 2024; status: recruiting.
02
Drugs
sintilimabpemetrexed
03
Conditions
leptomeningeal metastasis (LM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06431685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431685.